Interleukin 5

Function

Through binding to the interleukin-5 receptor, interleukin 5 stimulates B cell growth and increases immunoglobulin secretion—primarily IgA. It is also a key mediator in eosinophil activation.

Structure

IL-5 is a 115-amino acid (in human, 133 in the mouse) -long Th2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer.

Tissue expression

The IL-5 gene is located on chromosome 11 in the mouse, and chromosome 5 in humans, in close proximity to the genes encoding IL-3, IL-4, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are often co-expressed in Th2 cells. IL-5 is also expressed by eosinophils and has been observed in the mast cells of asthmatic airways by immunohistochemistry. IL-5 expression is regulated by several transcription factors including GATA3.

Clinical significance

IL-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease.

As of 2019, there are two FDA-approved monoclonal antibodies that inhibit IL-5, mepolizumab and reslizumab. Additionally, the antibody benralizumab blocks the interleukin-5 receptor. All three drugs are used to treat severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Another antibody, depemokimab (GSK3511294), ultra-long acting IL-5 inhibitor, is under development.

Some hydroxyethylaminomethylbenzimidazole analogs have shown IL-5 inhibition in vitro.

Effect on eosinophils

Eosinophils are terminally differentiated granulocytes found in most mammals. The principal role of these cells, in a healthy host, is the elimination of antibody bound parasites through the release of cytotoxic granule proteins. Given that eosinophils are the primary IL-5Rα-expressing cells, it is not surprising that this cell type responds to IL-5. In fact, IL-5 was originally discovered as an eosinophil colony-stimulating factor, is a major regulator of eosinophil accumulation in tissues, and can modulate eosinophil behavior at every stage from maturation to survival. Mepolizumab is a monoclonal antibody antagonist IL-5 which can reduce excessive eosinophilia.

In Hodgkin lymphoma, the typically-observed eosinophilia is thought to be attributable to an increased production of IL-5.

Interactions

IL-5 has been shown to interact with interleukin 5 receptor alpha subunit.

Receptors

The IL-5 receptor is composed of an α and a βc chain. The α subunit is specific for the IL-5 molecule, whereas the βc subunit also recognised by interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Glycosylation of the Asn196 residue of the Rα subunit appears to be essential for binding of IL-5.

References

References

1. (May 1993). "A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5". Nature.
2. (March 1989). "The IL-4 and IL-5 genes are closely linked and are part of a cytokine gene cluster on mouse chromosome 11". Somatic Cell and Molecular Genetics.
3. (April 1989). "Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5". Blood.
4. (February 1994). "Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion". The Journal of Experimental Medicine.
5. (May 1994). "Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines". American Journal of Respiratory Cell and Molecular Biology.
6. (2005). "Role of GATA-3 in IL-5 gene transcription by CD4+ T cells of asthmatic patients". International Archives of Allergy and Immunology.
7. (March 2003). "A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse". Journal of Immunology.
8. (June 1992). "Interleukin-5, eosinophils, and disease". Blood.
9. (8 January 2019). "Anti-interleukin-5 therapy for severe asthma: A new therapeutic option". Mayo Clinic.
10. (February 2023). "Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities". Annals of the Rheumatic Diseases.
11. (February 2022). "A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma". British Journal of Clinical Pharmacology.
12. (November 2019). "Discovery of benzimidazole analogs as a novel interleukin-5 inhibitors". European Journal of Medicinal Chemistry.
13. (June 1999). "Pharmacology of the eosinophil". Pharmacological Reviews.
14. (May 1986). "Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells". The Journal of Experimental Medicine.
15. (July 1996). "Eosinophilia in Hodgkin's disease: a role for interleukin 5". International Archives of Allergy and Immunology.
16. (November 1994). "Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF". The EMBO Journal.
17. (April 1995). "Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins". The Journal of Biological Chemistry.
18. (February 1992). "Molecular cloning and expression of the human interleukin 5 receptor". The Journal of Experimental Medicine.
19. (September 1991). "A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF". Cell.
20. (June 1993). "Reconstitution of the functional receptors for murine and human interleukin 5". The Journal of Experimental Medicine.
21. (September 2011). "A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α". Biochemistry.